{"id":"W2597768246","doi":"","title":"Preliminary results of a phase II study of brentuximab vedotin using a response adapted design for the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (BREVITY)","year":2016,"lang":"en","type":"article","venue":"Research Explorer (The University of Manchester)","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Wojskowy Instytut Medyczny; Universitätsklinikum Köln; Université de Lorraine; Assistance publique-Hôpitaux de Paris; Humanitas University; Aalborg Universitetshospital; Université de Namur; Università di Bologna; Všeobecná Fakultní Nemocnice v Praze; Memorial Sloan-Kettering Cancer Center; Rigshospitalet; Università degli Studi di Firenze; University of California, Los Angeles; Institut National de la Santé et de la Recherche Médicale; Gentofte Hospital; Barbara Ann Karmanos Cancer Institute; University of Toronto; Brigham and Women's Hospital; Emory University; Università Degli Studi di Modena e Reggio Emila; Bristol-Myers Squibb; BC Cancer Agency; Università degli Studi di Pavia; Aalborg Universitet; Univerzita Karlova v Praze","keywords":"Brentuximab vedotin; Medicine; Oncology; Internal medicine; Lymphoma; Chemotherapy; Hodgkin lymphoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003041559,0.001158899,0.001278456,0.0002691438,0.000314776,0.0007362033,0.0007361321,0.0009989409,0.003461635],"category_scores_gemma":[0.001535928,0.0004838145,0.0009643233,0.0002775238,0.0006765578,0.0005598307,0.0003015349,0.002429577,0.0006635493],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004341762,"about_ca_system_score_gemma":0.00105236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007209284,"about_ca_topic_score_gemma":0.001567792,"domain_scores_codex":[0.999395,0.0003738262,0.00002911663,0.00006015772,0.00004793608,0.00009402916],"domain_scores_gemma":[0.9988727,0.0002770518,0.0001465348,0.0001193141,0.00008447703,0.0004998694],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5192546,0.1431436,0.01059936,0.001204898,0.001377604,0.0005979516,0.0007146013,0.005272032,0.1860509,0.0004914452,0.00741474,0.1238784],"study_design_scores_gemma":[0.2478841,0.7235762,0.01734162,0.00002356816,0.0002880399,0.0003179754,0.00003950731,0.0008492141,0.006074179,0.0001967919,0.003378412,0.00003045804],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882389,0.0009930258,0.001696763,0.0006183848,0.0001208877,0.005115136,0.001530668,0.0001217429,0.001564495],"genre_scores_gemma":[0.9694595,0.001443849,0.00859371,0.001621936,0.0002360987,0.008646479,0.005209263,0.00008500672,0.004704238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003461635,"threshold_uncertainty_score":0.01608551,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2173316733654037,"score_gpt":0.3722261433574812,"score_spread":0.1548944699920776,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}